Literature DB >> 20827404

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Masao Omata, Laurentius A Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T P Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K Chawla, Unggul Budihusodo, Rino A Gani, C Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin.   

Abstract

INTRODUCTION: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations.
METHODS: The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements.
RESULTS: Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

Entities:  

Keywords:  Consensus statements; Diagnosis; Epidemiology; Hepatocellular carcinoma; Recommendations; Treatment algorithm

Year:  2010        PMID: 20827404      PMCID: PMC2900561          DOI: 10.1007/s12072-010-9165-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  396 in total

1.  Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization.

Authors:  Shiro Miyayama; Osamu Matsui; Keiichi Taki; Tetsuya Minami; Yasuji Ryu; Chiharu Ito; Koichi Nakamura; Dai Inoue; Kazuo Notsumata; Daisyu Toya; Nobuyoshi Tanaka; Takeshi Mitsui
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jan-Feb       Impact factor: 2.740

2.  Screening methods for early detection of hepatocellular carcinoma.

Authors:  K Kobayashi; T Sugimoto; H Makino; M Kumagai; M Unoura; N Tanaka; Y Kato; N Hattori
Journal:  Hepatology       Date:  1985 Nov-Dec       Impact factor: 17.425

3.  The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.

Authors:  Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; Nam-Joon Yi; Kuhn Uk Lee
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

4.  Coffee drinking and serum gamma-glutamyltransferase: an extended study of Self-Defense Officials of Japan.

Authors:  S Honjo; S Kono; M P Coleman; K Shinchi; Y Sakurai; I Todoroki; T Umeda; K Wakabayashi; K Imanishi; H Nishikawa; S Ogawa; M Katsurada; K Nakagawa; N Yoshizawa
Journal:  Ann Epidemiol       Date:  1999-07       Impact factor: 3.797

5.  Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan.

Authors:  Sheng-Nan Lu; Wei-Wen Su; Sheng-Shun Yang; Ting-Tsung Chang; Ken-Sheng Cheng; Jaw-Ching Wu; Hans Hsienhong Lin; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Chien-Hung Chen
Journal:  Int J Cancer       Date:  2006-10-15       Impact factor: 7.396

6.  Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein.

Authors:  H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

7.  Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue.

Authors:  Bobby Bhartia; Janice Ward; J Ashley Guthrie; Philip J Robinson
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

8.  Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation.

Authors:  Hye Jin Yoo; Jeong Min Lee; Min Woo Lee; Soo Jin Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Invest Radiol       Date:  2008-07       Impact factor: 6.016

9.  Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma.

Authors:  Ragaa E Omer; Anneleen Kuijsten; Abdelgadir M Y Kadaru; Frans J Kok; Mohammed O Idris; Ibrahim M El Khidir; Pieter van 't Veer
Journal:  Nutr Cancer       Date:  2004       Impact factor: 2.900

10.  Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.

Authors:  J W Chung; J H Park; J K Han; B I Choi; M C Han; H S Lee; C Y Kim
Journal:  Radiology       Date:  1996-01       Impact factor: 11.105

View more
  399 in total

1.  Hepatocellular carcinoma screening in a hepatitis B virus-infected Korean population.

Authors:  Seung Ha Park; Nae Yun Heo; Jong Ha Park; Tae Oh Kim; Sung Yeun Yang; Hyun Kuk Kim; Young Soo Moon; Chang Hoon Kim; Ki Tae Suk; Dong Joon Kim; Heon Young Lee
Journal:  Dig Dis Sci       Date:  2012-06-23       Impact factor: 3.199

2.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

3.  Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

Authors:  Robert J Wong; James Wantuck; Antonia Valenzuela; Aijaz Ahmed; Clark Bonham; Amy Gallo; Marc L Melcher; Glen Lutchman; Waldo Concepcion; Carlos Esquivel; Gabriel Garcia; Tami Daugherty; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 4.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 5.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

7.  CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis.

Authors:  Huan He; Jianxiong Wu; Mengya Zang; Weihu Wang; Xiuli Chang; Xiangmei Chen; Ruijun Wang; Zhiyuan Wu; Liming Wang; Dongmei Wang; Fengmin Lu; Zongtang Sun; Chunfeng Qu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

10.  Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.

Authors:  Pi-Yi Chang; Chun-Chieh Huang; Chao-Hung Hung; Chih-Yung Yu; Ding-Kwo Wu; Jen-I Hwang; Po-Chin Liang; Reng-Hong Wu; Wei-Lun Tsai; Yih-Jyh Lin; Yi-Sheng Liu; Huei-Lung Liang; Rheun-Chuan Lee; Chien-Hung Chen
Journal:  Liver Cancer       Date:  2018-03-29       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.